Drugs / Pneumosil
Pneumosil
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03896477 | Jul 2019 → Dec 2020 | streptococcal pneumonia | PATH | Completed | No outcome recorded |
| Phase 3 | NCT03197376 | Jun 2017 → Jun 2018 | streptococcal pneumonia | PATH | Completed | Met primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT06817421 | Jan 2026 → Mar 2028 expected | pneumococcal infection, pneumonia | Nick Fancourt | Recruiting | No outcome recorded |
| Phase 4 | NCT04945681 | Nov 2022 → Jan 2025 overdue | pneumococcal infection | London School of Hygiene and Tropical Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05175014 | Dec 2021 → Mar 2023 | — | Epicentre | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT05140720 | Jan → Feb 2022 | streptococcal pneumonia | Vabiotech | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-07-15 | Serum Institute of India Pvt. Ltd. | Regulatory Serum Institute’s Indigenous Pneumonia Vaccine Gets DCGI Approval seruminstitute.com ↗
The Drug Controller General of India V.G. Somani has approved Serum Institute of India Pvt Ltd’s indigenous pneumococcal polysaccharide conjugate vaccine, making it the first indigenously developed vaccine against pneumonia, the government said in a statement on Wednesday. |
| 2019-12-20 | Serum Institute of India Pvt. Ltd. | Regulatory A new pneumococcal vaccine is here! Why this matters seruminstitute.com ↗
The Serum Institute vaccine that was merely an ambitious idea over a decade ago has just been WHO-prequalified and will be made available to low- and middle-income countries for a target of US$2 per dose, an unprecedentedly low price for any pneumococcal vaccine. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-28 | Serum Institute of India Pvt. Ltd. | Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL' seruminstitute.com ↗ |
| 2020-07-15 | Serum Institute of India Pvt. Ltd. | Serum Institute’s Indigenous Pneumonia Vaccine Gets DCGI Approval seruminstitute.com ↗ |
| 2019-12-20 | Serum Institute of India Pvt. Ltd. | A new pneumococcal vaccine is here! Why this matters seruminstitute.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumosil | “The study will adopt a quasi-experimental design, with baseline and post-intervention surveys to evaluate changes in pneumococcal carriage, complemented by safety assessment in...” NCT04945681 ↗6“Safety and coverage of Pneumosil pneumococcal polysaccharide conjugate vaccine (10-valent PCV) in a camp for internally displaced persons in Somaliland.” PMID 41265006 ↗ Nov 2025 “campaigns consisting of a single full dose of a 10-valent PCV (Pneumosil), a single one-fifth dose of Pneumosil, or no campaign” PMID 39798587 ↗ Jan 2025 “Treatment Arm: Pneumosil” NCT06817421 ↗ |
| Known as | PCV10-SII | “PCV10-SII (PNEUMOSIL), a 10-valent PCV prequalified by the World Health Organization (WHO) in 2019, offers a cost-effective alternative.” PMID 42042812 ↗ Apr 20261“The 10-valent Pneumosil PCV (PCV10-SII) is currently licensed for use in children aged 6 weeks to 2 years.” PMID 41265006 ↗ Nov 2025 |
| Known as | SIIPL-PCV | “a novel ten-valent PCV (SIIPL-PCV) containing serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F” PMID 33516293 ↗ Jan 2021 |
| Modality | Vaccine | “a novel ten-valent pneumococcal conjugate vaccine” PMID 33516293 ↗ Jan 2021 |
| Route | Intramuscular | “Vaccines (0·5 mL SIIPL-PCV or 0·5 mL PHiD-CV) were administered at ages 6, 10, and 14 weeks by intramuscular injection.” PMID 33516293 ↗ Jan 2021 |